(Q37642786)

21 August 2017

1 reference

title

Role and rationale of gene therapy and other novel therapies in the management of NMIBC. (English)

1 reference

21 August 2017

0 references

Prasanna Sooriakumaran

series ordinal

3

object named as

Prasanna Sooriakumaran

1 reference

21 August 2017

Carlos Lojo Rial

1

1 reference

PubMed ID

19954289

21 August 2017

Daniel Wilby

series ordinal

2

1 reference

PubMed ID

19954289

21 August 2017

language of work or name

1 reference

1 December 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

1777-1782

1 reference

21 August 2017

12

1 reference

Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

The epidemiology of bladder and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Intravesical treatments of bladder cancer: review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Gene therapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Accumulation of nuclear p53 and tumor progression in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Current state of immunotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

Targeted therapies in bladder cancer--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.106

21 January 2018

Identifiers

DOI

10.1586/ERA.09.106

1 reference

21 August 2017

1 reference

PubMed ID

19954289